BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33860907)

  • 21. RAS Mutations in AUS/FLUS Cytology: Does it Have an Additional Role in BRAFV600E Mutation-Negative Nodules?
    Yoon JH; Kwon HJ; Lee HS; Kim EK; Moon HJ; Kwak JY
    Medicine (Baltimore); 2015 Jul; 94(27):e1084. PubMed ID: 26166089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Performance of Ultrasound Patterns by K-TIRADS and 2015 ATA Guidelines in Risk Stratification of Thyroid Nodules and Follicular Lesions of Undetermined Significance.
    Hong HS; Lee JY
    AJR Am J Roentgenol; 2019 Aug; 213(2):444-450. PubMed ID: 31039023
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk stratification of thyroid nodules with Bethesda category III results on fine-needle aspiration cytology: The additional value of acoustic radiation force impulse elastography.
    Zhao CK; Xu HX; Xu JM; Sun CY; Chen W; Liu BJ; Bo XW; Wang D; Qu S
    Oncotarget; 2017 Jan; 8(1):1580-1592. PubMed ID: 27906671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and prognostic value of a 7-panel mutation testing in thyroid nodules with indeterminate cytology: the SWEETMAC study.
    Bardet S; Goardon N; Lequesne J; Vaur D; Ciappuccini R; Leconte A; Monpeyssen H; Saguet-Rysanek V; Clarisse B; Lasne-Cardon A; Ménégaux F; Leenhardt L; Buffet C
    Endocrine; 2021 Feb; 71(2):407-417. PubMed ID: 32638211
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Fine-needle aspiration cytology of thyroid nodules: molecular diagnostics in a routine diagnostic setting].
    Eszlinger M; Neustadt M; Ruschenburg I; Neumann A; Franzius C; Adam S; Bacher K; Hach A; Hammoser R; Langvogt C; Molwitz T; Paschke R
    Dtsch Med Wochenschr; 2014 Mar; 139(10):476-80. PubMed ID: 24570192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples.
    Nikiforov YE; Ohori NP; Hodak SP; Carty SE; LeBeau SO; Ferris RL; Yip L; Seethala RR; Tublin ME; Stang MT; Coyne C; Johnson JT; Stewart AF; Nikiforova MN
    J Clin Endocrinol Metab; 2011 Nov; 96(11):3390-7. PubMed ID: 21880806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules.
    Nikiforov YE; Steward DL; Robinson-Smith TM; Haugen BR; Klopper JP; Zhu Z; Fagin JA; Falciglia M; Weber K; Nikiforova MN
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2092-8. PubMed ID: 19318445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular genotyping of follicular variant of papillary thyroid carcinoma correlates with diagnostic category of fine-needle aspiration cytology: values of RAS mutation testing.
    Lee SR; Jung CK; Kim TE; Bae JS; Jung SL; Choi YJ; Kang CS
    Thyroid; 2013 Nov; 23(11):1416-22. PubMed ID: 23590130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ultrasound criteria (EU-TIRADS) to identify thyroid nodule malignancy risk in adolescents. Correlation with cyto-histological findings.
    Yeste Fernández D; Vega Amenabar E; Coma Muñoz A; Arciniegas Vallejo L; Clemente León M; Planes-Conangla M; Iglesias Felip C; Sábado Álvarez C; Guillén Burrieza G; Campos-Martorell A
    Endocrinol Diabetes Nutr (Engl Ed); 2021 Dec; 68(10):728-734. PubMed ID: 34924161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
    Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC
    Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Novel Risk Stratification System for Thyroid Nodules With Indeterminate Cytology-A Pilot Cohort Study.
    Gomes-Lima CJ; Auh S; Thakur S; Zemskova M; Cochran C; Merkel R; Filie AC; Raffeld M; Patel SB; Xi L; Wartofsky L; Burman KD; Klubo-Gwiezdzinska J
    Front Endocrinol (Lausanne); 2020; 11():53. PubMed ID: 32132976
    [No Abstract]   [Full Text] [Related]  

  • 32. Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China.
    Guo HQ; Zhao H; Zhang ZH; Zhu YL; Xiao T; Pan QJ
    Dis Markers; 2014; 2014():912182. PubMed ID: 24591770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
    Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
    Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mutational analysis in the diagnostic work-up of thyroid nodules: the real impact in a center with large experience in thyroid cytopathology.
    Macerola E; Rago T; Proietti A; Basolo F; Vitti P
    J Endocrinol Invest; 2019 Feb; 42(2):157-166. PubMed ID: 29704233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Korean vs. American Thyroid Imaging Reporting and Data System in Malignancy Risk Assessment of Indeterminate Thyroid Nodules.
    Kang S; Kwon SK; Choi HS; Kim MJ; Park YJ; Park DJ; Cho SW
    Endocrinol Metab (Seoul); 2021 Oct; 36(5):1111-1120. PubMed ID: 34674501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
    Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
    Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Performance of Thyroid Nodule Risk Stratification Systems: Comparison of ACR-TIRADS, EU-TIRADS, K-TIRADS, and ATA Guidelines.
    Yucel S; Balci IG; Tomak L
    Ultrasound Q; 2023 Dec; 39(4):206-211. PubMed ID: 37918114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Can malignant thyroid nodules be distinguished from benign thyroid nodules in children and adolescents by clinical characteristics? A review of 89 pediatric patients with thyroid nodules.
    Buryk MA; Simons JP; Picarsic J; Monaco SE; Ozolek JA; Joyce J; Gurtunca N; Nikiforov YE; Feldman Witchel S
    Thyroid; 2015 Apr; 25(4):392-400. PubMed ID: 25627462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utilities of
    Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
    Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of the Bethesda System and the ACR TIRADS in an Endemic Goiter Region.
    Karaagac M; Sarigoz T; Ertan T; Topuz O
    Endocr Res; 2020 Nov; 45(4):226-232. PubMed ID: 32729365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.